Activation of receptor for advanced glycation end products - A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis

被引:641
|
作者
Schmidt, AM
Yan, SD
Wautier, JL
Stern, D
机构
[1] Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
[4] Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA
[5] Columbia Univ Coll Phys & Surg, Dept Cellular Biophys, New York, NY 10032 USA
[6] UFR Lariboisiere St Louis, Lab Biol Vasc & Cellulaire, Paris, France
关键词
glycoxidation; diabetes; nuclear factor-kappa B; inflammation; amyloid;
D O I
10.1161/01.RES.84.5.489
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and engages diverse ligands relevant to distinct pathological processes. One class of RAGE ligands includes glycoxidation products, termed advanced glycation end products, which occur in diabetes, at sites of oxidant stress in tissues, and in renal failure and amyloidoses. RAGE also functions as a signal transduction receptor for amyloid beta peptide, known to accumulate in Alzheimer disease in both affected brain parenchyma and cerebral vasculature. Interaction of RAGE with these ligands enhances receptor expression and initiates a positive feedback loop whereby receptor occupancy triggers increased RAGE expression, thereby perpetuating another wave of cellular activation. Sustained expression of RAGE by critical target cells, including endothelium, smooth muscle cells, mononuclear phagocytes, and neurons, in proximity to these ligands, sets the stage for chronic cellular activation and tissue damage. In a model of accelerated atherosclerosis associated with diabetes in genetically manipulated mice, blockade of cell surface RAGE by infusion of a soluble, truncated form of the receptor completely suppressed enhanced formation of vascular lesions. Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands. Future studies using mice in which RAGE expression has been genetically manipulated and with selective low molecular weight RAGE inhibitors will be required to definitively assign a critical role for RAGE activation in diabetic vasculopathy. However, sustained receptor expression in a microenvironment with a plethora of ligand makes possible prolonged receptor stimulation, suggesting that interaction of cellular RAGE with its ligands could be a factor contributing to a range of important chronic disorders.
引用
收藏
页码:489 / 497
页数:9
相关论文
共 50 条
  • [41] Advanced glycation end products and diabetic complications
    Stitt, AW
    Jenkins, AJ
    Cooper, ME
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (09) : 1205 - 1223
  • [42] Advanced Glycation End Products and Diabetic Complications
    Singh, Varun Parkash
    Bali, Anjana
    Singh, Nirmal
    Jaggi, Amteshwar Singh
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2014, 18 (01): : 1 - 14
  • [43] Advanced glycation end products in diabetic corneas
    Kaji, Y
    Usui, T
    Oshika, T
    Matsubara, M
    Yamashita, H
    Araie, M
    Murata, T
    Ishibashi, T
    Nagai, R
    Horiuchi, S
    Amano, S
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (02) : 362 - 368
  • [44] Diabetic nephropathy and advanced glycation end products
    Menè, P
    Festuccia, F
    Polci, R
    Pugliese, F
    Cinotti, GA
    ADVANCED GLYCATION END PRODUCTS IN NEPHROLOGY, 2001, 131 : 22 - 32
  • [45] Advanced glycation end products and diabetic retinopathy
    Milne, Ross
    Brownstein, Seymour
    AMINO ACIDS, 2013, 44 (06) : 1397 - 1407
  • [46] Accumulation of Advanced Glycation End Products in Canine Atherosclerosis
    Chiers, K.
    Vandenberge, V.
    Ducatelle, R.
    JOURNAL OF COMPARATIVE PATHOLOGY, 2010, 143 (01) : 65 - 69
  • [47] The role of advanced glycation end products in the development of atherosclerosis
    Peppa M.
    Uribarri J.
    Vlassara H.
    Current Diabetes Reports, 2004, 4 (1) : 31 - 36
  • [48] Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-β:: implications for diabetic atherosclerosis
    Cantero, Anne-Valerie
    Portero-Otin, Manuel
    Ayala, Victoria
    Auge, Nathalie
    Sanson, Marie
    Elbaz, Meyer
    Thiers, Jean-Claude
    Pamplona, Reinald
    Salvayre, Robert
    Negre-Salvayre, Anne
    FASEB JOURNAL, 2007, 21 (12): : 3096 - 3106
  • [49] Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer
    Jiao, Li
    Taylor, Philip R.
    Weinstein, Stephanie J.
    Graubard, Barry I.
    Virtamo, Jarmo
    Albanes, Demetrius
    Stolzenberg-Solomon, Rachael Z.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (07) : 1430 - 1438
  • [50] Soluble receptor of advanced glycation end-products and endothelial dysfunction in COPD
    Urban, Matthias H.
    Valipour, Arschang
    Kiss, Dora
    Eickhoff, Philipp
    Funk, Georg-Christian
    Burghuber, Otto C.
    RESPIRATORY MEDICINE, 2014, 108 (06) : 891 - 897